Table 3.
Baseline demographics, clinical characteristics, mean striatal DaT SBR and BMP concentrations (adjusted for age and sex) in GBA1 N409S + PD, N409S + NMC, sPD, and HC.
| 1 | 2 | 3 | 4 | ||||
|---|---|---|---|---|---|---|---|
| N409S+ PD n = 76 | N409S+ NMC n = 178 | sPD n = 379 | HC n = 190 | P value 1 vs 2 | P value 1 vs 3 | P value 2 vs 4 | |
| Age (years), mean (SD)a | 62.79 (10.22) | 62.15 (6.71) | 61.94 (9.66) | 60.67 (11.16) | |||
| Age at onset (years), mean (SD) | 58.52 (10.88) | 59.94 (9.93) | N/A | 0.2945 | N/A | ||
|
Mean Striatal DaT SBR, mean (SD) missing |
1.28 (0.52) | 2.79 (0.57) | 1.39 (0.39) | 2.57 (0.56) | <0.0001 | 0.1003 | 0.7039 |
| 13 | 5 | 4 | 3 | ||||
|
Disease duration (months), median (range) |
31.72 | 4.2 | N/A | <0.0001α | N/A | ||
| (0.30, 85.23) | (0.40, 35.83) | ||||||
| Female Sex, n (%) | 33 (43.42%) | 106 (59.55%) | 129 (34.04%) | 67 (35.26%) | 0.0180 | 0.1189 | <0.0001 |
|
MDS-UPDRS III Off, mean (SD) missing |
26.87 (11.11) | 2.60 (3.90) | 20.89 (8.79) | 1.19 (2.15) | <0.0001 | 0.0001 | <0.0001 |
| 15 | 1 | 0 | 2 | ||||
|
MoCA, median (range) missing |
27 | 27 | 28 | 28 | 0.2107α | 0.0056α | <0.0001α |
| (15.00, 30.00) | (16.00, 30.00) | (17.00, 30.00) | (26.00, 30.00) | ||||
| 0 | 0 | 0 | 0 | ||||
| Total di-18:1-BMP, median (range)b | 5.20 | 4.38 | 3.53 | 3.77 | |||
| (0.70, 26.49) | (0.38, 33.51) | (0.21, 38.02) | (0.39, 22.03) | ||||
| Total di-22:6-BMP, median (range) | 14.14 | 14.51 | 10.61 | 10.42 | 0.9184 | 0.0014 | <0.0001 |
| (3.74, 88.97) | (3.16, 115.74) | (1.18, 76.76) | (1.25, 85.89) | ||||
| 2,2’-di-22:6-BMP, median (range) | 9.65 | 9.54 | 6.83 | 6.37 | 0.9248 | 0.0001 | <0.0001 |
| (2.22, 66.35) | (0.81, 87.08) | (0.81, 59.27) | (0.60, 65.96) |
Pairwise comparisons that showed significance at p value <0.0125 (after Bonferroni correction applied due to multiple comparisons) are shown in bolded font.
PD Parkinson’s disease, NMC non-manifesting carriers, sPD sporadic PD, HC healthy control, SD standard deviation, DaT dopamine transporter, SBR specific binding ratio, MDS-UPDRS movement disorders society-unified Parkinson’s disease rating scale, MoCA Montreal cognitive assessment, BMP bis(monoacylglycerol)phosphate.
αComputed using Mann–Whitney U-test.
aThe overall F-test was non-significant thus pairwise comparisons were not computed.
bThe overall test was non-significant thus pairwise comparisons were not computed.